TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01378988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: For sedation according to protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: For sedation according to protocol
Study: NCT01545726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW039
Description: QAW039 was supplied as capsules for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was supplied as capsules for oral administration.
Study: NCT02230735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bipivacaine 0.5% with epinephrine
Description: Total of 14 ml of bupivacaine hydrochloride 0.5% with epinephrine 1:200,000, 7ml in right uterosacral ligament, 7ml in left uterosacral ligament

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: (placebo for bupivacaine)
Study: NCT03635463

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: twin block appliance
Description: a functional appliance that enhances mandibular growth in growing patients made from vaccum sheets (esthetic)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: modified twin block appliance
Description: a convetional twin block functional appliance that enhances mandibular growth in growing patients
Study: NCT03959163

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Quick MRI
Description: A quick MRI scan takes about 15 mins or less. No IV or sedation will be necessary. The participant will be required to lie flat and still during the test. A parent will be allowed to be with the participant while they are in the scanner. The machine will produce loud intermittent sounds of banging or knocking so they will have to wear protective headphones. They can listen to music if they would like. If they are less than 1 year old, they will be swaddled and can be held during the test. If a child needs to have a parent in the scanner, it is ideal if the parent can have their head near the participant's legs and arms stretched out to hold the child's hands. If the parent needs to be by the patient's head, it can be accomplished by the parent lying head to head with the child or the parent lying on the child. Ideally they are lying head to head, or just outside of the scanner reaching in.
Study: NCT02790996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Vancomycin is an antibiotic used to treat a number of bacterial infections.It is recommended intravenously as a treatment for complicated skin infections, bloodstream infections, endocarditis, bone and joint infections, and meningitis caused by methicillin-resistant S. aureus.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Vancomycin is an antibiotic used to treat a number of bacterial infections.It is recommended intravenously as a treatment for complicated skin infections, bloodstream infections, endocarditis, bone and joint infections, and meningitis caused by methicillin-resistant S. aureus.
Study: NCT04059510

Intervention type: PROCEDURE
Intervention: rectovaginal swab
Description: Self taken rectal and vaginal swab

Intervention type: PROCEDURE
Intervention: rectovaginal swab
Description: Self taken rectal and vaginal swab

Intervention type: PROCEDURE
Intervention: pregnancy test
Description: Urine pregnancy test

Intervention type: PROCEDURE
Intervention: pregnancy test
Description: Urine pregnancy test

Intervention type: PROCEDURE
Intervention: Menstrual cup
Description: Menstrual cup vaginal fluid collection

Intervention type: PROCEDURE
Intervention: Blood test
Description: Venous blood sample

Intervention type: PROCEDURE
Intervention: Blood test
Description: Venous blood sample

Intervention type: OTHER
Intervention: Focus group
Description: Focus group responses will be audio-recorded, transcribed, and analysed by developing a coding framework and identifying emerging themes
Study: NCT00746070

Intervention type: OTHER
Intervention: with the clinical treatment ( ex adrenalectomy or spironolactone
Description: with the clinical observational study
Study: NCT02306746

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TARGET protocol EN 1.5 kcal/mL
Description: Enteral feed 1.5 kcal/mL

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: TARGET protocol EN 1.0 kcal/mL
Description: Enteral feed 1.0 kcal/mL
Study: NCT03531385

Intervention type: DIAGNOSTIC_TEST
Intervention: Central sensitisation
Description: Central Sensitization Inventory, which is a comprehensive self-report inventory to assess the overlapping symptom dimensions of central sensitisation syndrome will be used to identify participants with central sensitisation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Central sensitisation
Description: Central Sensitization Inventory, which is a comprehensive self-report inventory to assess the overlapping symptom dimensions of central sensitisation syndrome will be used to identify participants with central sensitisation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropathic pain
Description: Frequency of neuropatic pain will be investigated using Pain Detect Questionnaire

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropathic pain
Description: Frequency of neuropatic pain will be investigated using Pain Detect Questionnaire

Intervention type: OTHER
Intervention: Sleep disturbance
Description: Assessment of sleep disturbance will be assessed by Pittsburgh Sleep Quality Index

Intervention type: OTHER
Intervention: Sleep disturbance
Description: Assessment of sleep disturbance will be assessed by Pittsburgh Sleep Quality Index

Intervention type: OTHER
Intervention: Quality of life
Description: Quality of life will be assessed by the Nottingham Health Profile

Intervention type: OTHER
Intervention: Quality of life
Description: Quality of life will be assessed by the Nottingham Health Profile
Study: NCT02093884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Messaging Intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Referral
Study: NCT01347801

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLP-1
Description: GLP-1 1,2pmol/kg/min i.v. infusion for 4 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLP-1
Description: GLP-1 1,2pmol/kg/min i.v. infusion for 4 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Saline)
Description: Normal saline (NaCl 0,9%)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Saline)
Description: Normal saline (NaCl 0,9%)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Saline)
Description: Normal saline (NaCl 0,9%)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Saline)
Description: Normal saline (NaCl 0,9%)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TNF-alfa
Description: 1000ng/m2 BSA/hour i.v. infusion for 4-6 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TNF-alfa
Description: 1000ng/m2 BSA/hour i.v. infusion for 4-6 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TNF-alfa
Description: 1000ng/m2 BSA/hour i.v. infusion for 4-6 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TNF-alfa
Description: 1000ng/m2 BSA/hour i.v. infusion for 4-6 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TNF-alfa
Description: 1000ng/m2 BSA/hour i.v. infusion for 4-6 hours
Study: NCT00859547

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rThrombin, 1000 IU/mL
Description: rThrombin,1000 IU/mL, 1000 IU/mL, applied topically to the bleeding site during a single surgery procedure on Day 1.
Study: NCT01302483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% tetracaine HCL with 0.05% oxymetazoline HCL
Description: 1 sham injection along with 3 sprays of Kovacaine Nasal Spray in each nostril; a 4-minute interval between every set of sprays. The total dose of 3% tetracaine HCL with 0.05% oxymetazoline HCL was 18 mg/0.3 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Injection
Description: Each subject received both an injection along with 3 sprays of isotonic saline sham in each nostril; a 4-minute interval between every set of sprays.
Study: NCT01638663

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolvaptan
Description: 15 mg pr day for 1 day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet Unikalk 1 pr day for 1 day
Study: NCT02863614

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 600 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam 1 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT01347801

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TNF-alfa
Description: 1000ng/m2 BSA/hour i.v. infusion for 4-6 hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OGTT
Description: Oral glucose tolerance test with 75 g glucose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: OGTT
Description: Oral glucose tolerance test with 75 g glucose

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OGTT
Description: Oral glucose tolerance test with 75 g glucose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: OGTT
Description: Oral glucose tolerance test with 75 g glucose

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OGTT
Description: Oral glucose tolerance test with 75 g glucose
Study: NCT02863614

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01173601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRI
Description: Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRI
Description: Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SSRI
Description: Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study.
Study: NCT01347801

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IVGTT
Description: Intravenous glucose tolerance test with infusion of 20% glucose matching the glucose profile of the corresponding OGTT

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IVGTT
Description: Intravenous glucose tolerance test with infusion of 20% glucose matching the glucose profile of the corresponding OGTT
Study: NCT01106599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0623
Description: Repeating oral dose
Study: NCT01347801

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IVGTT
Description: Intravenous glucose tolerance test with infusion of 20% glucose matching the glucose profile of the corresponding OGTT
Study: NCT02629029

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pre-op CTA with IV contrast
Description: Preoperative mapping of perforators by computed tomography angiography (CTA) could prove valuable in head and neck free flap transfer and shorten the operation time significantly. This modality could provide useful information for H\&N cancer reconstruction in difficult cases, especially in patients with large or through-and-through defects that might need multiple perforators in flap design. In addition, near-infrared (NIR) fluorescence imaging using indocyanine green (ICG) angiography can provide robust, intraoperative, objective data to optimize the free flap skin paddle design while potentially minimizing patient morbidity.

Intervention type: DEVICE
Group type: OTHER
Intervention: Computed tomography angiography (CTA)
Study: NCT01033539

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic strain ATCC PTA 4659
Description: Placebo control containing no probiotic strain of ATCC PTA 4659 High dose of ATCC PTA 4659 1\*10 10 CFU/bag Low dose of ATCC PTA 4659 1\*10 8 CFU/bag
Study: NCT01347801

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IVGTT
Description: Intravenous glucose tolerance test with infusion of 20% glucose matching the glucose profile of the corresponding OGTT
Study: NCT01033539

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic strain ATCC PTA 4659
Description: Placebo control containing no probiotic strain of ATCC PTA 4659 High dose of ATCC PTA 4659 1\*10 10 CFU/bag Low dose of ATCC PTA 4659 1\*10 8 CFU/bag

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic strain ATCC PTA 4659
Description: Placebo control containing no probiotic strain of ATCC PTA 4659 High dose of ATCC PTA 4659 1\*10 10 CFU/bag Low dose of ATCC PTA 4659 1\*10 8 CFU/bag
Study: NCT03876717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colesevelam Hydrochloride
Description: Colesevelam is a sequestrant that binds bile acids in the intestinal lumen, the bile acids are then excreted with the feces. Colesevelam is registered for treating hypercholesterolemia but it is as other sequestrants (e.g. cholestyramine and colestipol) effective against bile acid diarrhoea.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Inactive placebo tablets over-encapsulated with DB caps AAA
Study: NCT03089021

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mulligan mobilization
Description: mobilization with movement for spinous process or facet joint.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: maitland mobilization
Description: posterioanterior of spinous process or facet joint.
Study: NCT02754570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine
Description: Pilocarpine will be administered 4 times in addition to latanoprost.
Study: NCT04608721

Intervention type: OTHER
Intervention: Postpartum Anxiety
Description: Postpartum anxiety will be assessed at 1-3 days (T1), 1(T2), 3 (T3), 6 (T4) and 12 months (T5) postpartum by using the State-Trait Anxiety Inventory (STAI) with a score ≥40 serving as a positive screen.
Study: NCT01121146

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Hip Replacement
Description: Comparison of Marathon and Enduron polyethylene

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Hip Replacement
Description: Comparison of Marathon and Enduron polyethylene
Study: NCT00733785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone XR
Description: Rosiglitazone extended release formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone XR
Description: Rosiglitazone extended release formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone XR
Description: Rosiglitazone extended release formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone XR
Description: Rosiglitazone extended release formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone XR
Description: Rosiglitazone extended release formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone XR
Description: Rosiglitazone extended release formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone XR
Description: Rosiglitazone extended release formulation
Study: NCT01467011

Intervention type: DRUG
Intervention: Enteric-coated Mycophenolate Sodium
Description: 1440mg/day for 6 months posttransplant
Study: NCT04118465

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: external cephalic version
Description: external cephalic version
Study: NCT01290315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose (FCM)
Description: One 500 mg dose at 100 mg/minute (Cohort I) or 750 mg dose at 100 mg/minute (Cohort II)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Sucrose / Iron Dextran
Description: One 500 mg dose of IV iron sucrose administered over 4 hours (Cohort I), or a 750 mg dose of IV iron dextran administered as a 25 mg test dose over 5 minutes followed by a 725 mg dose over 3 hours if no adverse reaction to test dose is observed after 60 minutes (Cohort II)
Study: NCT04585724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO
Study: NCT00705679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir disoproxil fumarate
Description: 200 mg/300 mg tablet
Study: NCT04585724

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT00705679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir disoproxil fumarate placebo
Description: placebo tablet
Study: NCT04585724

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT00705679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir disoproxil fumarate placebo
Description: placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: 300 mg tablet
Study: NCT04585724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Given PO
Study: NCT04400188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHR-1316
Description: Given injection
Study: NCT03273673

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biofeedback Intervention
Description: Visual and Tactile Biofeedback
Study: NCT03964350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: The 0.8 g/kg body weight dose of gelatin alcohol will be divided into an average of 10 servings of 0.08 g/kg each. The 0.8 g/kg dose is equivalent to 4 standard drinks, where a standard drink is defined as one 12 oz beer, one 5 oz glass of wine, or one 1.5 oz shot of 80 proof alcohol.~The 0.4 g/kg body weight dose of gelatin alcohol will be divided into an average of 5 servings of 0.08 g/kg each. The 0.4 g/kg dose is equivalent to 2 standard drinks, where a standard drink is defined as one 12 oz beer, one 5 oz glass of wine, or one 1.5 oz shot of 80 proof alcohol.
Study: NCT00705679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate placebo
Description: placebo tablet
Study: NCT03964350

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo comparator will be individual servings of back cheery sugar-free jello.
Study: NCT03788057

Intervention type: OTHER
Group type: OTHER
Intervention: ICS dose reduction
Description: If control of symptoms is maintained (evaluation based on clinical symptoms solely), every 3 months the dose of ICS is halved according to GINA guidelines, until the control is lost or the lowest daily dose is reached (200 mcg, calculated as budesonide equivalent).~In the case of loss of asthma control, beta-mimetic will be administered (temporarily) and return to the chronic administration of the previous, twice higher dose of ICS is restored (or further increase of treatment). In severe exacerbations, inclusion of oral steroids will be considered.
Study: NCT03901131

Intervention type: DRUG
Intervention: Norethisterone enantate/estradiol valerate (Mesigyna, BAY98-7040)
Description: Follow clinical administration
Study: NCT03564652

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Balanced energy-protein (BEP)
Description: Lactating women in the intervention arms will receive approximately 800 Kcal/day and around 16-21 gram of protein in a day in the form of ready-to-use supplement.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Balanced energy-protein (BEP)
Description: Lactating women in the intervention arms will receive approximately 800 Kcal/day and around 16-21 gram of protein in a day in the form of ready-to-use supplement.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: A single prophylaxis dose of 20 mg/kg in suspension form, reconstituted by trial staff before dose administration by the same.
Study: NCT02314663

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COMBINED STRATEGY
Description: Participants in the intervention group will be supplied with: a) printed matter containing information on the disease and its management (this will be handed out at each of the follow-up visits); b) mobile-telephone text messages containing guideline summaries, reminders of forthcoming appointments and/or arrangements for making new appointments in the event of non-attendance (in the periods between visits); and, c) self-report cards to check compliance with recommendations (across the entire follow-up).
Study: NCT02803736

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Acupuncture involves the insertion of extremely thin needles through skin at strategic points on human body. Many Western practitioners view the acupuncture as a device to stimulate nerves, muscles and connective tissue, and believe that it can increases blood flow.
Study: NCT02803736

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: acupuncture
Description: Acupuncture involves the insertion of extremely thin needles through skin at strategic points on human body. Many Western practitioners view the acupuncture as a device to stimulate nerves, muscles and connective tissue, and believe that it can increases blood flow.
Study: NCT01719796

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regional analgesia infusion
Study: NCT03421522

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICBN preservation surgery
Description: For participants randomized to the ICBN preserving technique, surgeons will perform axillary dissection in which the second ICBN, just inferior to the axillary vein, will be preserved. Surgeons will be asked to indicate whether the ICBN nerve was fully preserved, partially preserved, or sacrificed.~All study participants will receive anesthetic management at the discretion of the attending physician, which will be documented.
Study: NCT03679975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole Oral Soluble film (ROSF) 50 mg
Description: Enrolled subjects underwent an instrumental evaluation of swallowing safety before and after administration of a single dose of the ROSF formulation containing 50 mg of riluzole.